A Study on the Impact of Rabeprazole-induced Elevated Stomach pH on APO-Dabigatran Exposure in Healthy Volunteers
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
Open-label, crossover study recruiting 46 healthy male volunteers comparing the absorption of
APO-dabigatran 150 mg per oral (PO) in the absence or presence of a proton pump inhibitor.
Participants will serve as their own control when comparing dabigatran exposure in the
absence or presence of the proton pump inhibitor, Rabeprazole 20 mg.